Logo image of LFCR

LIFECORE BIOMEDICAL INC (LFCR) Stock Fundamental Analysis

USA - NASDAQ:LFCR - US5147661046 - Common Stock

6.69 USD
+0.15 (+2.29%)
Last: 10/15/2025, 8:00:02 PM
6.69 USD
0 (0%)
After Hours: 10/15/2025, 8:00:02 PM
Fundamental Rating

2

Overall LFCR gets a fundamental rating of 2 out of 10. We evaluated LFCR against 56 industry peers in the Life Sciences Tools & Services industry. LFCR has a bad profitability rating. Also its financial health evaluation is rather negative. LFCR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LFCR had negative earnings in the past year.
LFCR had a negative operating cash flow in the past year.
In the past 5 years LFCR reported 4 times negative net income.
LFCR had negative operating cash flow in 4 of the past 5 years.
LFCR Yearly Net Income VS EBIT VS OCF VS FCFLFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.53%, LFCR is in line with its industry, outperforming 41.07% of the companies in the same industry.
The Return On Equity of LFCR (-93.52%) is worse than 80.36% of its industry peers.
Industry RankSector Rank
ROA -18.53%
ROE -93.52%
ROIC N/A
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
LFCR Yearly ROA, ROE, ROICLFCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

1.3 Margins

The Gross Margin of LFCR (31.27%) is worse than 71.43% of its industry peers.
In the last couple of years the Gross Margin of LFCR has grown nicely.
The Profit Margin and Operating Margin are not available for LFCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
LFCR Yearly Profit, Operating, Gross MarginsLFCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

More info and screens

2

2. Health

2.1 Basic Checks

LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
LFCR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, LFCR has more shares outstanding
The debt/assets ratio for LFCR is higher compared to a year ago.
LFCR Yearly Shares OutstandingLFCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
LFCR Yearly Total Debt VS Total AssetsLFCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.26, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.26, LFCR is not doing good in the industry: 73.21% of the companies in the same industry are doing better.
LFCR has a Debt/Equity ratio of 2.68. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.68, LFCR is doing worse than 89.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.68
Debt/FCF N/A
Altman-Z 0.26
ROIC/WACCN/A
WACC9.02%
LFCR Yearly LT Debt VS Equity VS FCFLFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M

2.3 Liquidity

LFCR has a Current Ratio of 2.84. This indicates that LFCR is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.84, LFCR perfoms like the industry average, outperforming 55.36% of the companies in the same industry.
LFCR has a Quick Ratio of 1.77. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.77, LFCR perfoms like the industry average, outperforming 46.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 1.77
LFCR Yearly Current Assets VS Current LiabilitesLFCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for LFCR have decreased strongly by -669.18% in the last year.
Looking at the last year, LFCR shows a small growth in Revenue. The Revenue has grown by 0.47% in the last year.
Measured over the past years, LFCR shows a decrease in Revenue. The Revenue has been decreasing by -4.25% on average per year.
EPS 1Y (TTM)-669.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
Revenue 1Y (TTM)0.47%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%-3.81%

3.2 Future

LFCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.41% yearly.
Based on estimates for the next years, LFCR will show a very strong growth in Revenue. The Revenue will grow by 21.24% on average per year.
EPS Next Y41.64%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue Next Year3.51%
Revenue Next 2Y7.18%
Revenue Next 3Y11.96%
Revenue Next 5Y21.24%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LFCR Yearly Revenue VS EstimatesLFCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
LFCR Yearly EPS VS EstimatesLFCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LFCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFCR Price Earnings VS Forward Price EarningsLFCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LFCR Per share dataLFCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

LFCR's earnings are expected to grow with 23.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.63%
EPS Next 3Y23.41%

More info and screens

0

5. Dividend

5.1 Amount

LFCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFECORE BIOMEDICAL INC

NASDAQ:LFCR (10/15/2025, 8:00:02 PM)

After market: 6.69 0 (0%)

6.69

+0.15 (+2.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-03 2025-10-03
Earnings (Next)12-31 2025-12-31
Inst Owners76.4%
Inst Owner ChangeN/A
Ins Owners1.8%
Ins Owner Change10.82%
Market Cap247.73M
Analysts80
Price Target10.2 (52.47%)
Short Float %7.32%
Short Ratio19.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.55%
Min EPS beat(2)-207.19%
Max EPS beat(2)38.08%
EPS beat(4)2
Avg EPS beat(4)-39.23%
Min EPS beat(4)-207.19%
Max EPS beat(4)38.08%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.38%
Min Revenue beat(2)1.03%
Max Revenue beat(2)3.72%
Revenue beat(4)4
Avg Revenue beat(4)4.13%
Min Revenue beat(4)1.03%
Max Revenue beat(4)7.32%
Revenue beat(8)5
Avg Revenue beat(8)2.28%
Revenue beat(12)6
Avg Revenue beat(12)-5.39%
Revenue beat(16)7
Avg Revenue beat(16)-14.35%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.53%
EPS NQ rev (3m)-3.83%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)-3.81%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.92
P/FCF N/A
P/OCF N/A
P/B 5.22
P/tB 8.44
EV/EBITDA N/A
EPS(TTM)-1.27
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS3.48
BVpS1.28
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.53%
ROE -93.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.27%
FCFM N/A
ROA(3y)-17.69%
ROA(5y)-20.17%
ROE(3y)-118.33%
ROE(5y)-99.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.85%
GM growth 5Y4.91%
F-Score3
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 2.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 167.12%
Cap/Sales 10.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 1.77
Altman-Z 0.26
F-Score3
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)177.04%
Cap/Depr(5y)161.61%
Cap/Sales(3y)15.06%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-669.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.71%
EPS Next Y41.64%
EPS Next 2Y28.63%
EPS Next 3Y23.41%
EPS Next 5YN/A
Revenue 1Y (TTM)0.47%
Revenue growth 3Y-11.48%
Revenue growth 5Y-4.25%
Sales Q2Q%-3.81%
Revenue Next Year3.51%
Revenue Next 2Y7.18%
Revenue Next 3Y11.96%
Revenue Next 5Y21.24%
EBIT growth 1Y-17.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year656.28%
EBIT Next 3Y130.51%
EBIT Next 5YN/A
FCF growth 1Y24.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.07%
OCF growth 3YN/A
OCF growth 5YN/A